Placeholder Banner

China Phase I Agreement Represents Important Step Towards Addressing Biotech Issues

January 15, 2020
Media Contact
Karen Batra

Washington, D.C. (January 15, 2020) – BIO President and CEO Jim Greenwood released the following statement today regarding the signing of Phase One of the trade agreement with China:

“Trade issues with China have long been a priority for BIO and our members. We appreciate the Administration’s hard work and leadership and welcome the completion of this important first phase of the agreement.

“We are currently reviewing the details, but we are pleased to see important commitments for agricultural biotechnology, biopharmaceuticals, and GM microorganisms, in addition to commitments related to forced technology transfer and intellectual property. We look forward to working closely with the Administration to monitor the implementation and enforcement of these provisions. 

“Completion of the phase-one agreement is an important first step.  More work is needed as we move to the next phase of this important negotiation. Our trade relationship with China is vital for America’s farmers, our scientists and our entrepreneurs. We must build on this momentum to ensure we have the type of 21st Century agreement with China that is balanced, enforceable and reflective of key sectors of America’s economy and our future.” 

Discover More
Exclusion of biologics provisions in revised USMCA sets dangerous precedent for future trade talks, including with China Puts American jobs, intellectual property and leadership in medical innovation at risk WASHINGTON – BIO President and CEO Jim…
Event Brought Together Biopharma Executives and Investors from Around the World for Deal Making and Partnering Opportunities
BIO President and CEO Jim Greenwood today applauded a letter authored by Senators Pat Roberts (R-Kan.) and Debbie Stabenow (D-Mich.) to President Trump urging him to continue prioritizing in U.S.-China trade negotiations the need for China to…